Dror Bashan - 15 Aug 2023 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Signature
/s/ Eyal Rubin, POA
Issuer symbol
PLX
Transactions as of
15 Aug 2023
Net transactions value
$0
Form type
4
Filing time
17 Aug 2023, 16:30:58 UTC
Previous filing
03 Apr 2024
Next filing
20 Oct 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLX Common Stock Award +800,000 +74% 1,885,458 15 Aug 2023 By Trust F1, F2
holding PLX Common Stock 68,000 15 Aug 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended. Of such shares, 200,000 shares were fully-vested upon grant and the remaining 600,000 shares vest over a two-year period beginning on the date of grant in eight equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.
F2 To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.